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Summary: The capacity of L-649,923-sodium 
( ßS, -yR * )-4-(3-( 4-acetyl-3-hydroxy-2-propylphenoxy)-
propylthio)--y-hydroxy-ß-methylbenzene butanoate-to 
block vascular receptors of leukotriene D4 ( L TD4 ) was 
examined in the conscious rat. Hindquarter (HQ), renal, 
and mesenteric blood flow and vascular resistance were 
evaluated in the conscious rat chronically equipped with 
miniaturized Doppler probes for organ blood flow mea-
surement by directional pulsed Doppler technique. In ad-
dition, cardiac outpul was measured by thermodilution 
technique in conscious rats equipped with minither-
mistors in the ascending aorta. Systemic hemodynamic 
variables. mean arterial pressure, and heart rate were 
monitored through femoral catheters. L TD4 (I or 10 
J.Lg/kg) produced a marked dose dependent increase in the 
mesenteric vascular resistance associated with a marked 
decrease in blood flow whereas no consistent effects 
were demonstrated in the renal circulation. L TD4 • at I 
Cysteinylleukotrienes (LT) arepotent mediators 
produced by the 5-lipoxygenase pathway of arachi-
donate metabolism (I). The L Ts have been shown 
tobe extremely potent substances in producing pul-
monary derangements (2,3) similar to the human 
disorder asthma (4), and to produce typical inflam-
matory reactions including wheal and tlare (5 ,6). 
Furthermore, LTs have been implicated in several 
trauma situations such as burns, hone fracture, and 
surgical wounds (7 -I 0) as weil as endotoxic shock 
( 11, 12). Cardiac and vascular derangements seem 
to be of primary importance in leukotriene-induced 
shock states (for review see ref. 13). 
The potential involvement of LTs in multiple 
pathophysiologic processes stimulated substantial 
efforts in designing and testing compounds that 
might antagonize LT actions in various organs. 
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J.Lg/kg. increased the HQ blood flow whereas the higher 
dose of LTD4 produced a biphasic response: an early in-
crease followed by a decrease in blood flow. Infusion of 
L TD4 • 3 J.Lg/kg per min over 10 min decreased cardiac 
output and increased total peripheral resistance. 
L-649,923 (10 or 30 mg/kg, i.v.) effectively blocked the 
L TD4-induced mesenteric constriction and the second I 
phase of HQ vasoconstriction but did not modify the , 
LTD4 induced HQ vasodilation. L-649,923 also effec-
tively attenuated the cardiac effects of LTD4 infusion. I 
These studies suggest that L-649,923 could preserve car-
diac and vascular functions in pathologic states mediated 
by cysteinylleukotrienes, such as traumatic or endotoxin 
shock. Key Words: Leukotriene D4 -Cardiovascular 
system- Leukotriene antagonist- Mesenteric blood 
tlow-Renal blood flow-Hindquarter blood flow-
Anaphylaxis. 
Several L T antagonists have already been tested 
and described in detail (for review see ref. 14) with 
the primary view of prophylactic or therapeutic ca-
pacity in asthma. However, alt the LT antagonists 
described so far demonstrated only limited potency 
and partial specificity. Furthermore, only a limited 
number of studies attempted to examine the ca-
pacity of LT antagonists to block the vascular re-
ceptors of L Ts. Vascular actions of such antago-
nists might be an essential part of a proteelive ef-
fect in situations where systemic cardiovascular 
derangements (e.g., cardiac anaphylaxis, shock) 
rather than pulmonary are the primary pathophysi-
ologic processes. 
Our laboratory has previously described the ca-
pacity of two known LT antagonists, FPL-55712 
and LY-171883, toblock vascular responses to 
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LTD4 and LTE4 (15). Whereas both compounds 
have demonstrated partial blocking capacity of the 
constrictive effect of L TD4 on specific vascular 
beds. the doses that were necessary to produce the 
proteelive action were quite high and elicited in-
trinsic systemic and regional hemodynamic re-
sponses ( 15). 
More recently, a new LT antagonist. L-649,923. 
has been described (16). This compound has been 
shown to be a competitive antagonist of the pulmo-
nary effects of LTD4 in vitro andin vivo (16). How-
ever. the capacity of L-649,923 toblock cardiac and 
vascular LTD4 receptors has not been studied as 
yet. 
In this paper we have examined the capacity of 
L-649,923 to block LTD4 actions on selected vas-
cular beds and the cardiac output of the conscious 
rat. This species has been selected for these sturlies 
because LTs produce no consistent pulmonary ef-
fects and have no effect on platelet aggregation 
( 17). Furthermore. by utilizing the directional 
pulsed Doppler velocimetry for blood flow mea-
surements it is possible to examine several discrete 
vascular responses instantaneously in the con-
scious state that cannot be accomplished by other 
methods. 
MATERIALS AND METHODS 
Male Sprague-Dawley rats (Taconic Farms) weighing 
250-350 g were used in all studies (n = 26). Surgical pro-
cedures were performed under anesthesia after intramus-
cular injection of ketamine ( 130 mg/kg) and acepromazine 
( 1.3 mg/kg) solution. Experiments were carried out on 
the conscious unrestrained rats 1-3 days after operation. 
All rats were housed individually in standard plastic 
cages with food and water ad libitum. 
Regional blood flow measurements with directional 
pulsed Doppler technique 
The directional pulsed Doppler method was selected to 
measure organ blood flow in the hindquarter. renal, and 
mesenteric vessels. Though it does not allow quantitative 
blood flow monitoring, this method is superior compared 
with other available techniques because: (a) it can be 
used chronically in conscious animals; (b) it allows con-
tinuous on-line recording of blood flow; and (c) it can de-
tect instantaneous and transient changes in blood flood 
within seconds after the drug administration. Haywood et 
al. ( 18) have shown that the velocity signals recorded 
from the Doppler flow probes are directly and reliably 
proportional to changes in true volume flow measured by 
electromagnetic flowmetry. 
Miniaturized Doppler flow probes were implanted 
around the lower abdominal aorta for hindquarter (HQ) 
blood tlow measurement. The superior mesenteric (M) 
and the left renal (R) arteries were also implanted with 
such probes by the method previously described by Hay-
wood et al. (18). Briefly. a midline laparotomy was per-
formed, and the M, R, and Iower abdominal aorta above 
its bifurcation were carefully isolated under a dissecting 
microscope. Miniaturized Doppler flow probes (Valpey-
Fisher) were then loosely sutured (6-0 silk) around each 
vessel. The insulated wire Ieads of the probes were tun-
neled beneath the skin, exteriorized at the nape of the 
neck, and soldered to a receptacle that was then attached 
to the skull with small screws and dental acrylic. The 
femoral artery and vein were cannulated with polyeth-
ylene catheters (PE-50) that were also tunneled beneath 
the skin to exit at the neck. Catheters were regularly 
tlushed (0.2 ml) with heparinized saline ( 100 U/ml) and 
secured by a soft spring wire attahced to the animal's 
neck with an adhesive collar. 
On the day of the experiment the arterialline was con-
nected to a pressure transducer (Narco Bio-Systems 
model RP 1500i) coupled to a strain gauge coupler (Narco 
Bio-Systems type 7179) and a biotachometer coupler 
(Narco Bio-Systems type 7032). Mean arterial blood 
pressure (MAP) and heart rate (HR) were continuously 
recorded on a Narcotrace 80 computerized dynograph 
and sampled (automatically or manually) at 15-60 s in-
tervals by a Northstar-Hazeltine computer. A connector 
line was attached between the blood flow receptacle and 
a directional pulsed Doppler flowmeter (University of 
Iowa, Bioelectrical Engineering). Output signals of 
Doppler shifts >4 kHz were simultaneously transformed 
to mean flow velocity (kHz) and recorded continuously 
on the Narcotrace 80 through universal couplers (type 
7178). Local vascular resistance was calculated by di-
viding the MAP by the Doppler shift in kilohertz, as pre-
viously described ( 15). lt is noteworthy that measure-
ments of MAP from the femoral artery cannula in the rat 
are virtually the same as the MAP in other arteries (e.g., 
brachial, mesenteric) in normal, hypotensive, or hyper-
tensive states (19). Changes in regional blood flow and 
local vascular resistance were further expressed as per-
cent changes from control values. No differences in the 
basal signallevel were found between the various experi-
mental groups. 
Experimental protocols 
On the day of experiment each animal was allowed to 
stabilize for at least 30 min while basal (control) Ievels of 
the hemodynamic variables were recorded. Vehicle injec-
tions (0.9% NaCI, 300 ~L i.v.) were used as controls for 
injection effects. To assess the consistency of the various 
vascular responses, a bolus injection of norepinephrine 
(0.3-1 fJ.g/kg i. v .) was used; this test dose of norepineph-
rine caused a prompt increase in MAP, a decrease in HR, 
and a decreased blood flow in HQ. R. and M. After the 
stabilization period each animal was scheduled to one of 
the following protocols: (a) administration of L TD4 (I or 
10 fJ.g/kg, i.v.) as bolus injections in ascending order; or 
(b) administration of LTD4 (I or 10 J.l.g/kg, i.v.) 15 min 
after treatment with the LT antagonist L-649,923 (10 or 
30 mg/kg. i. v ., given over 0.5-1 min). 
Measurement of cardiac output 
In eight additional rats, the effect of L-649,923 on 
L TD4 actions on cardiac outpul and total peripheral resis-
tance (TPR) was investigated. Because bolus injections 
of L TD4 induced only transient changes in hemodynamic 
variables that arenot possible to detect by using the ther-
modilution method, a continuous infusion of L TD4 was 
used in these experiments. The rats were anesthetized 
with pentobarbitone (40 mg!kg i.p.) and PE-50 tubing was 
inserted into the femoral arteries. These catheters were 
tunneled beneath the back skin and exited at the back of 
the neck as previously described. An incision was made 
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TABLE 1. Hemodynamic effects of L-649,923 in the conscious rat 
Phase 1 
~ Blood flow (%) ~ Resistance (%) 
~MAP ~HR 
(mm Hg) (beats/min) HQ R M HQ R M 
10 mg/kg -5 ± 1 +3 ± 12 +20 ± 6a -2S ± 1S + 111 ± 39G -IO:t5 + 173 ± 10S -49 ::t Sb 
30 mg/kg - 3S ::t 5b - 135 ::t 33b -90 ± Sb -92 ± 4a -75 ::t J6b + S07 :t 275a +693 ± 25oa + 1565 ± 756a 
Phase 2 
10 mg/kg + 13 ::t 2b -46 ::t Sb +6 ::t 5 +41 ± 14a -13 ± 4 +4 :t 3 -19 ± 8 -49 ± 811 
30 mglkg +24 ± 4b -51 ± Jlb + 15 ± 6a + 19 ± 11 +72 ± 42 + 15 ± 4a +S ::t 12 -2S ± 15 
MAP, mean arterial pressure; HR, heart rate; HQ, hindquarter; R, renal; M, mesenteric; n, 6-10. Maximal changes recorded 5-10 
min after drug administration. L-649,923 was injected intravenously. Values indicate mean ± SEM. 
Significance from baseline: "P < 0.05, bp < 0.01 (Student-Newman-Keul test). 
at the midline of the neck from the cricoid to the clavicle, 
and PE-50 tubing was inserted into the right atrium 
through the external jugular vein. The left common ca-
rotid artery was exposed and Jigated, and a thermistor 
(MX2-780-33 model THMP f 1.5, Teflon reusable, Co-
lumbus Instruments) was advanced through the carotid 
into the ascending aorta (placement above the aortic 
valve was confirmed in each animal at the end of the ex-
periment and by the shape of the dilution curve). Alliines 
were secured by a soft spring wire through the cage as 
described earlier. Twenty-four hours after surgery, the ar-
terial line was connected to a blood pressure transducer 
for hemodynamic recordings. 
The cardiac output was measured by thermodilution 
technique as previously described (20). ln brief, the 
thermistor was attached to the computerized Cardiomax 
II (CMX2-780-k with the miereprobe option R, Columbus 
Instruments). The dead space of the venous line was first 
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flushed with 0.05 ml of 0. 9% (wt/vo)) NaCI (saline) at 
room temperature (22°C); afterabrief stabilization period 
( 10 s to ensure normal core ternperature) an additional 
injection of 0.2 ml normal saline {22°C) was rapidly in-
jected using a 1 ml syringe. Cardiac output was recorded 
in the following way: a control period of 15 min included 
two to three cardiac output measurements to test for con-
sistency and placement of the probe and also to get con-
1 
trol values for MAP and HR. Continuous infusion of 
LTD4 (3 f.Lg/kg- 1 per min-I) over 10 min (total LTD4 dose 
30 f.Lg/kg) into the jugular vein (27 J..LI/min) was done by 
1 
means of a Harvard infusion pump (Harvard lnstru- 1 
ments) before and 15 min after treatment with L-649,923 
(30 mg/kg). The timer on the automatic data collection 
system was started at the beginning of the L TD4 infusion, 
and data points were taken at time (t) ~. t3, t5, t 10, and t30 
min. The animal was allowed to completely recover from 
the first L TD4 infusion (at least 1.5 h) before the adminis-
112 84 
L·649, 923 
30 mg/kg 
IV 
132 
FIG. 1. Original tracing of the hemodynamic responses to L-649,923 in the conscious rat. AP, arterial pressure; HQ, hindquarter; 
R, renal; M, mesenteric. Values above the pressure tracing denote Ievels of mean arterial pressure and heart rate at the baseline 
30 s and 3 min after the injection of L-649,923 intravenously. 
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TADLE 2. BaseUne values of mean arterial pressure 
(MAP), heart rate (HR), regional blood jlow, and 
vascu/ar resistance before LTD4 administration in 
the conscious rat 
n s LIO L 30 
MAP (mm Hg) II 114 = 4 121 = 4 126 = 4 
HR (beats/min) II 394 = 14 371 = 11 359 = 15 
Blood flow CkHz) 
HQ II 3.7 = 0.5 3.3 ::!:: 0.4 3.2 = 0.3 
R 10 3.2 = 0.6 3.4 = 0.6 3.4 ::!:: 0.6 
M 9 5.1 = 0.7 5.5 ::!:: 0.6 5.8 ::!:: 0.7 
Resistance (mm HglkHz) 
HQ II 36 = 4 42 ::!:: 5 43 ::!:: 4 
R 10 44 = 5 45 ::!:: 6 47 = 7 
M 9 23 ::!:: 2 27 = 5 27 = 5 
Values (mean = SEM) indicate Ievels immediately before the com-
mencement of LTD4 administration after pretreatments with saline (s). 
10 mglkg L-649,923 CL 10), or 30 mg/kg CL 30). HQ. hindquarter: R. renal: 
M. mesenteric: n. number of rats: LTD4• leukotriene D,. 
tration of the antagonist and the infusion of L TD4 re-
peated. Total peripheral resistance was calculated by di-
viding the MAP by the cardiac output; values of cardiac 
output and TPR were further indexed per unit of weight 
(kg). 
Drugs 
Pure synthetic LTD4 and L-649,923 were kindly pro-
vided by Merck Frosst. L TD4 was aliquoted in distilled 
water and kept frozen ( -70°C) until used. L-649,923 was 
dissolved in saline before its use. Each aliquot was 
thawed only once and diluted with 0.9% NaCJ to a final 
volume of 200-300 JLI for injection into the animal. 
Statistics 
Data are presented in text and figures as mean ± SEM 
for the indicated number of rats. Analysis of variance 
(ANOVA) with repeated measures and ANOVA followed 
by the Student Newman Keul test, Dunnett's test, or 
Kruskal-Wallis test was used for statistical evaluation of 
the data. Where appropriate, a two-tailed paired Stu-
dent's t test was also used. Differences were considered 
significant when the p value was <0.05. 
RESULTS 
lnfluence of L-649, 923 on blood pressure and heart 
rate responses to LTD4 
L-649,923 at the higher dose (30 mg/kg i.v.) in-
duced initial ( .. phase 1 ") hypotensive (- 37 ± 5 
mm Hg, p < 0.01) and strong bradycardic ( -135 ± 
33 beats/min, p < 0.01) responses. These effects 
became apparent 30 s after the drug administration 
and were followed by the pressor effect ("phase 
2"), which reached its maximum 5 min after the 
drug injection and subsided in 15 min (Table 1, Fig. 
1). The baseline values of hemodynamic param-
eters immediately before L TD4 administration were 
not different in L-649,923-treated rats compared 
with saline-treated rats (Table 2). 
Intravenous injection of L TD4 induced moderate 
increases in blood pressure and heart rate (Fig. 1). 
MEAN ARTERIAL PRESSURE 
LTD4 10 110/kg 
(n = 11·12) 
HEART RATE 
oL_j_jW1ill_ __ _l__~ ~--
o 10 30 0 10 30 
L649923 ( mg/kg) 
FIG. 2. Maximal changes in mean arterial pressure and heart 
rate after l TD,. administration in L-649,923-treated rats. LTD,. 
(1-10 ~g/kg) was injected intravenously before (open bars) 
and 15 min after intravenous injection of L-649,923 at doses 
10 mg/kg (hatched bars) and 30 mg/kg (cross-hatched bars). 
Vertical bars denote SEM. Asterisk indicates statistical sig-
nificance by Student-Newman-Keul test (*p < 0.05). 
L-649,923 blocked the pressor response to the low 
dose of L TD4 ( 1 !J.g/kg) but only partially attenuated 
the effect of the high dose (Fig. 2). 
Influence of L-649,923 on blood vessel responses 
to LTD4 
L-649,923 induced transient dilator/constrictor 
responses in HQ, R, and M blood vessels (Fig. 1, 
Table 1). At the low dose (10 mg/kg) an initialrenal 
vasoconstriction followed by a vasodilation in all 
three vascular beds was observed whereas the 
higher dose (30 mg/kg) induced vasoconstriction in 
all three vascular beds. However, all these re-
sponses subsided within 5-l 0 min. The blood flow 
values before L TD4 administration in L-649,923-
treated animals did not significantly differ from 
Ievels after saline (Table 2). 
Bolus injection of LTD4 produced differential ef-
fects on the R, M, and HQ vascular beds. In the 
mesenteric circulation (Fig. 3) LTD4 (1 or 10 IJ.g/kg) 
produced pronounced vasoconstriction ( + 116 ± 
44% and + 294 ± 69%, p < 0.01 vs. control), which 
was associated with marked reduction in mean 
blood tlow (- 35 ± 9% and -64 ± 5%, p < 0.01 
vs. control). L-649,923 (10 and 30 mg/kg, i.v.) com-
J Cardiovasc Pharmacol, Vol. /3, No. 2, /989 
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FIG. 3. Maximal changes in mesenteric blood flow and vas· 
cular resistance after L TD,. administration in L-649,923· 
treated rats. L TD4 (1-1 0 .,a.g/kg) was injected intravenously 
before (open bars) and 15 min after intravenous injection of 
L-649,923 at doses of 10 mg/kg (hatched bars) and 30 mg/kg 
(cross-hatched bars). Vertical bars indicate SEM. Asterisks 
indicate statistical significance by Student-Newman-Keul 
test (*p < 0.05, **p < 0.01 ). 
pletely blocked the changes in MBF and mean vas-
cular resistance (MVR) produced by the low dose 
of LTD4 (I JJ.g/kg). The higher dose of L-649,923 
also effectively blocked the effects of LTD4 though 
not completely (Fig. 3). 
In the HQ circulation, LTD4 produced biphasic 
effects, i.e., an increase ( + 22 ± 5%, p < 0.01 vs. 
control) in blood flow at the low dose followed by a 
decrease ( -16 ± 4%, p < 0.01 vs. control) at the 
higher dose. L-649,923 blocked only the secondary 
phase: the increase in hindquarter vascular resis-
tance and decrease in hindquarter blood flow 
(Fig. 4). 
In the renal circulation, no statistically significant 
responses were monitored after L TD4, although a 
slight tendency for reduction of renal blood flow 
and an increase in renal vascular resistance was no-
ticed. L-649,923 did not modify the LTD4 effect in 
this region (Fig. 5). 
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FIG. 4. Maximal changes in hindquarter blood flow and vas-
cular resistance after L TD,. administration in L-649,923-
treated rats. L TD4 (1-10 .,a.g/kg) was injected intravenously 
before (open bars) and 15 min after intravenous injection of 
L-649,923 at doses of 10 mg/kg (hatched bars) and 30 mg/kg 
(cross-hatched bars). Vertical bars indicate SEM. Asterisks 
indicate statistical significance by Student-Newman-Keul 
test (*p < 0.05). 
Effect of L-649,923 on cardiac output response to 
LTD4 infusion 
Infusion of L TD4 to the conscious rat produced a 
slight increase in mean arterial pressure and heart 
rate (Fig. 6). These changes were not significantly 
affected by L-649,923. LTD4 infusion produced a 
marked decrease in cardiac output that was accom-
panied by an increase in TPR (Fig. 7); both vari-
ables slowly returned to basal Ievels upon cessation 
of the infusion. L-649,923, at a dose of 30 mg/kg, 
did not significantly attenuate the initial decrease in 
cardiac output and the increase in TPR produced 
by LTD4 infusion but totally blocked the later re-
duction in cardiac output and increase in TPR 
(Fig. 7). 
DISCUSSION 
The cardiac and vascular responses produced by 
LTD4 in this study are consistent with previous re-
ports in the anesthetized and conscious rat (15, 17, 
21 ,22). The profound decrease in cardiac output is 
most probably the result of reduction in 0 2 delivery 
to the heart due to decrease in coronary blood flow 
because L TD4 has been shown to produce pro-
found coronary constriction in the rat coronary 
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FIG. 5. Maximal changes in renal blood flow and vascular 
resistance after L TD4 administration in L-649,923-treated 
rats. L TD4 (1-1 0 f.LQ/kg) was injected intravenously before 
(open bars) and 15 min after intravenous injection of 
L-649,923 at doses of 10 mg/kg (hatched bars) and 30 mg/kg 
(cross-hatched bars). Vertical bars indicate SEM. 
vessels (21) whereas no direct myocardial actions 
of LTD4 were found in this species (23). 
The vascular responses to LTD4 in the rat are 
most probably mediated by L TD4 receptors on the 
vascular smooth muscle because they are not 
blocked or modified by any antagonist of the 
known autacoids (24) nor are they mediated by cy-
cloxygenase metabolites of arachidonic acid ( 15). 
The nature of the vascular receptors of L Ts has 
been only sparsely explored. Most of the pharma-
cologic sturlies using L T antagonists have focused 
on bronchopulmonary preparations or other 
nonvascular smooth muscles (e.g., ileal). However, 
blockade of the coronary and other vascular re-
ceptors to L Ts might be of critical importance in 
view of protecting the heart and other essential 
organs from the consequences of systemic anaphy-
laxis or other forms of tissue injury where large 
amounts of LTs are produced (7,9,10). 
The two LT antagonists, FPL-55712 and 
LY-171883, have been shown toblock the effect of 
L TD4 at doses that already produce intrinsic car-
diovascular effects ( 15) and even these doses 
blocked only part of the vascular response. Thus, 
FPL-55712 (10 mg/kg) or LY-171883 (30 mg/kg) 
blocked approximately 50% of the vasoconstriction 
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FIG. 6. Effect of continuous intravenous infusion of L TD4 (3 
f.LQ/kg per min over 10 min) on mean arterial pressure (MAP) 
and haart rate (HR) in rats treated with L-649,923 (30 mg/kg 
i.v.). Values (mean ± SEM) in the left panel denote baseline 
Ieveis of MAP and HR immediately before LTD4 infusion, 
solid lines indicate infusion period, and dashed lines indi-
cate postinfusion period. The F and P values in the figure 
denote statistical difference between the groups by ANOVA 
with repeated measures. 
produced in the HQ, R, and M vessels in this same 
experimental model. 
Interestingly, LY-171883 but not FPL-55712 also 
blocked the vasodilation produced by L TD4 or 
LTE4 in the HQ (15). 
The newer L T antagonist tested in this study, 
L-649,923, produced clear dose dependent pressor 
effects in the conscious rat that followed abrief ini-
tial hypotension and bradycardia. Furthermore, 
L-649, 923 produced biphasic effects in the blood 
vessels tested. The low dose increased the blood 
tlow in the HQ, R, and M circulation, in part be-
cause of direct vasodilation; the higher dose pro-
duced a secondary constrictor response. The na-
ture of the vasodilation and the secondary vaso-
constriction produced by this drug is still obscure. 
Some intrinsic agonistic activity of L-649,923 might 
be preserved in this preferential antagonist of leu-
kotrienes. Release of pressor mediators (e.g., cate-
cholamines) is Contradieted by the finding that a 
profound hypotensive response accompanied the 
vasoconstriction. In any case, the hemodynamic 
responses provoked by L-649,923 were short 
Iasting and all the hemodynamic indexes were 
normal at the time of the LTD4 administration. 
L-649,923, at a dose of 30 mg/kg, completely 
blocked the increase in the mesenteric vascular re-
sistance after I JLg/kg L TD4 and preserved the tlow 
to the mesenteric region; this dose of L-649,923 still 
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FIG. 7. Effect of continuous intravenous infusion of L T04 (3 
~g/kg per min over 10 min) on cardiac index (Cl) and total 
peripheral resistance index (TPAI) in rats treated with 
L-649,923 (30 mg/kg i.v.). Values (mean ± SEM) in the left 
panel denote baseline Ievels of Cl and TPRI immediately be-
fore LTD4 infusion, solid lines indicate infusion period, and 
dashed lines indicate postinfusion period. The F and P 
values in the figure denote statistical difference between the 
groups by ANOVA with repeated measures. Asterisks denote 
statistical difference between L-649,923-treated and L TD4 
group by Student-Newman-Keul test rP < 0.05, ••p < 0.01 ). 
blocked >60% of the mesenteric response to the 
higher dose ( 10 j.t.g/kg) of L TD4 • This dose of 
L-649,923 also completely blocked the HQ vaso-
constriction produced by the high dose of L TD4 • 
Furthermore, L-649,923 at 30 mg/kg was very ef-
fective in attenuating the decrease in cardiac output 
produced by the infusions of L TD4 suggesting that 
this L T antagonist also blocked the coronary effect 
of LTD4 • 
The actions of L-649,923 described in this model 
are most probably the result of the direct actions of 
L-649,923 on LT receptors. This conclusion is 
based on previous pharmacologic and biochemical 
sturlies showing that L-649,923 is a competitive 
L TD4 antagonist and does not interact with hista-
mine, serotonin, thromboxane A2, or other auta-
coid receptors (16). Furthermore, in the rat, the ef-
fects of L TD4 are independent of cyclooxygenase 
metabolites of arachidonate, histamine, acetylcho-
line, or catecholamines (15,20). However, the initial 
decrease in cardiac outpul and increase in TPR 3 
min after the start of the L TD4 infusion were not 
significantly blocked by L-649,923. 
In summary, this study presents evidence on the 
J Cardiovasc Pharmacol, Vol. /3, No. 2. /989 
efficacy of L-649,923 to block vascular receptors of 
L TD4 • Therefore, it is suggested that such a com-
pound could exert a protective role in situations 
where coronary or other peripheral arterioles are 
exposed to constrictor Ievels of L Ts, as anticipated 
in systemic anaphylaxis (25). However, further 
studies are necessary to fully explore the intrinsic 
activity of this compound and especially its poten-
tial acute constrictive effect on the coronary 
vessels. 
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